KALRN
Kalirin
Protein Summary
Promotes the exchange of GDP by GTP. Activates specific Rho GTPase family members, thereby inducing various signaling mechanisms that regulate neuronal shape, growth, and plasticity, through their effects on the actin cytoskeleton. Induces lamellipodia independent of its GEF activity. Huntington's disease (HD), a neurodegenerative disorder characterized by loss of striatal neurons, is caused by an expansion of a polyglutamine tract in the HD protein huntingtin. This gene encodes a protein that interacts with the huntingtin-associated protein 1, which is a huntingtin binding protein that may function in vesicle trafficking. [provided by RefSeq, Apr 2016]
- ENST00000240874
- ENSP00000240874
- ENSG00000160145
- ENST00000291478
- ENSP00000291478
- DUET
- DUO
- HAPIP
- TRAD
- DUO
- CHD5
- DUET
- TRAD
- CHDS5
- HAPIP
- ARHGEF24
Most Knowledge About | Knowledge Value
(0 to 1 scale) | ||
|---|---|---|---|
protein domain | 1 | ||
molecular function | 0.96 | ||
trait | 0.93 | ||
transcription factor perturbation | 0.88 | ||
virus perturbation | 0.76 | ||
Protein Classes
IDG Development Level Summary
These are targets about which virtually nothing is known. They do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 125.56 (req: < 5)
Gene RIFs: 35 (req: <= 3)
Antibodies: 158 (req: <= 50)
These targets do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 125.56 (req: >= 5)
Gene RIFs: 35 (req: > 3)
Antibodies: 158 (req: > 50)
- OR - satisfy the following criterion:
Gene Ontology Terms: 26
Target has at least one ChEMBL compound with an activity cutoff of < 30 nM - AND - satisfies the preceding conditions
Active Ligand: 0
Target has at least one approved drug - AND - satisfies the preceding conditions
Active Drug: 0